Medtronic, Inc. (NYSE: MDT) reported Q1 EPS of $0.93, $0.01 better than the analyst estimate of $0.92. Revenue for the quarter came in at $4.27 billion versus the consensus estimate of $4.25 billion.

Medtronic, Inc. reaffirmed FY2014 guidance. Company also reaffirmed its commitment to Covidien transaction (NYSE: COV).

For earnings history and earnings-related data on Medtronic, Inc. (MDT) click here.